Multiple myeloma (MM) is a malignancy of differen-Multiple myeloma (MM) is the prototypic monoclonal Bcell neoplasm that is derived from the autonomous proliferation of plasma cells and associated with paraprotein production and osteolytic bone lesions. MM primarily affects middle-aged to elderly patients. Blacks and males are affected more often than whites and females. 1 MM has remained an incurable disease, and effective therapeutic approaches are urgently required for patients with MM at different risk groups. Standard prognostic factors include serum  2 -microglobulin, C-reactive protein, bone marrow plasma cell morphology, and plasma cell proliferation (plasma cell labeling index). 1-3 These factors are independently associated with prognosis of patients with MM. Recently, there is considerable interest in characterizing genomic markers to establish prognostic models that allow a better estimation of an individual patient's prognosis.Chromosomal abnormalities are among the most important prognostic parameters for patients with MM. Of particular note, deletions of 13q remain independent adverse prognostic factors. 4 -6 However, conventional karyotyping has been hampered by the slow growth of MM cells in cell cultures, and chromosomal abnormalities are often missed by this technique. Of the cases studied, 50 to 70% showed normal karyotypes originating from the myeloid elements. 7-11 Therefore, cell-targeting methods are essential for the analysis of genomic aberrations in MM.Fluorescent in situ hybridization (FISH) allows detection of chromosomal aberrations in both actively dividing cells and interphase nuclei. Recently, the cytoplasm immunoglobulin (Ig) enhanced interphase FISH has been used to detect the most common genomic abnormalities in 351 patients with MM, including deletions of 13q14 and 17p13.1 and 14q32 translocations [t(4,14)(p16;q32), t(14;16)(q32;q23), and t(11;14)(q13;q32)]. 12 Genomic aberrations have been detected in 54.2% of the tested population for 13q14 deletions, 33.1% for 14q32 translocations, and 10.7% for the 17p13.1 deletion. 12 Importantly, three distinct prognostic groups have been identified, including those with a median survival time of 24.7 months [the t(4;14) and/or t(14;16), and/or 17p13.1 deletion], 42.3 months [13q14 deletions without the t(4;14), t(14;16), or 17p13.1 deletion], and 50.5 months [only the